CV Sciences, Inc. (CVSI)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CV Sciences, Inc. (CVSI)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CV Sciences, Inc. (“CV Sciences” or the “Company”) (NASDAQ: CVSI). The investigation concerns whether CV Sciences and certain of its officers and/or directors have violated federal securities laws.
On August 20, 2018, Citron Research (“Citron”) published a report addressing a CV Sciences patent application for CVSI-007 titled “Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction” (the “Patent”). According to the Citron report, the U.S. Patent and Trademark Office (“USPTO”) made a non-final rejection decision and mailed CV Sciences a letter indicating the non-final rejection status of its Patent on June 6, 2017, and then made a final rejection decision and mailed CV Sciences a letter indicating the final rejection status of its Patent on December 20, 2017. The Citron report alleged that CV Sciences never disclosed to investors the USPTO’s decisions concerning the Company’s Patent. On this news, CV Sciences’ stock price fell $2.40, or 36.31%, to close at $4.21 on August 20, 2018.
If you are aware of any facts relating to this investigation, or purchased CV Sciences shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.